Gene ther­a­py play­er Affinia aims to go pub­lic, hop­ing to raise big mon­ey in ef­fort to re­make AAVs

Nine months af­ter Affinia Ther­a­peu­tics raised $110 mil­lion in a Se­ries B, the biotech has set its eyes on the Nas­daq.

The MA-based pre­clin­i­cal gene ther­a­py biotech, which got $60 mil­lion in start­up cap­i­tal from New En­ter­prise As­so­ciates, F-Prime and At­las in 2019, filed an S-1 with the SEC on Tues­day, an­nounc­ing ini­tial plans to go pub­lic and pen­cil­ing in a $100 mil­lion raise. Affinia plans to list un­der the tick­er $AF­TX.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER